96 -7 (81) 2025 - Kholiev B.O. - TREATMENT OF MYCOPLASMA PNEUMONIAE INFECTION IN CHILDREN

TREATMENT OF MYCOPLASMA PNEUMONIAE INFECTION IN CHILDREN

Kholiev B.O. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Mycoplasma pneumoniae (MP) causes Mycoplasma pneumoniae pneumonia (MPP) in children and adolescents, with clinical symptoms characterized by intermittent irritating cough, accompanied by headache, fever, and muscle pain. This paper aims to investigate the current research status and key focus areas in MP infection, particularly the common laboratory diagnostic methods and clinical treatment of Mycoplasma pneumoniae. Laboratory diagnostic methods include molecular assays, serological antibody detection, rapid antigen detection, and isolation and culture. Polymerase chain reaction (PCR) is considered the gold standard due to its high sensitivity and specificity

Keywords: Mycoplasma pneumoniae, laboratory diagnosis, treatment, children, antibody test

First page

512

Last page

514

For citation:Kholiev B.O. - TREATMENT OF MYCOPLASMA PNEUMONIAE INFECTION IN CHILDREN//New Day in Medicine 7(81)2025 512-514 https://newdayworldmedicine.com/en/new_day_medicine/7-81-2025

List of References

  1. Steinbach WJ, Fisher BT. International collaborative on contemporary epidemiology and diagnosis of invasive fungal disease in children. J Pediatric Infect Dis Soc. (2017) 6:S1–2. doi: 10.1093/jpids/pix039
  2. Ahangarkani F, Shokohi T, Rezai MS, Ilkit M, Mahmoodi Nesheli H, Karami H, et al. Epidemiological features of nosocomial candidaemia in neonates, infants and children: a multicentre study in Iran. Mycoses. (2020) 63:382–94.
  3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. (2007) 20:133–63.
  4. Tukhtaboevna M. Z. Choosing an Antihistamine to Treat Seasonal Allergies //INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES. – 2022. – Т. 1. – №. 4. – С. 401-407.
  5. Armstrong G. Z., Wasley A., Simard et al. The prevalence of hepatitis С virus infection in the United States, 1999 through. 2002. Ann. Intern. Med. 2006; 144: 705-741.
  6. Melhem A., Stem M., Shibolet O. et al, Treatment of chronic hepatitis С virus infection via antioxidants. Results of a phase clinical trial. J. CIin. Gastroenterol. 2005; 39: 737-742.
  7. Okanue L, Sakamoto S., Iton Y. et al. Побочные эффекты лечения хронического гепатита С высокими дозами интер¬ферона. J. Hepatol. 1996; 25: 283-291.
  8. Ibrokhimovna, M. M. . (2024). Improvement of Primary Prophylaxis and Treatment of Spontaneous Bacterial Peritonitis Complicated in Virus Etiology Liver Cirrhosis. Journal of Intellectual Property and Human Rights, 3(4), 19–25. Retrieved from http://journals.academiczone.net/index.php/jiphr/article/view/2506
  9. Mukhammadieva M.I. (2022). Modern clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis //Texas Journal of Medical Science. – 2022.- P. 86-90

    file

    download